寧波方正(300998.SZ):提升智能裝備產量
格隆匯6月15日丨有投資者向寧波方正(300998.SZ)提問:公司智能裝備這一塊22年收入增速以及毛利率都有較大提升,這一部分公司後續是如何規劃的呢,毛利率以及收入佔比能繼續提升嗎?
寧波方正回覆:公司智能裝備主要為注塑機和模具生產塑料件而配套提供的智能化、自動化流水線,主要包括嵌件組裝注塑取件集成、門板柔性焊接線、自動化生產線、以機器視覺為核心的多場景應用等。2022年智能裝備營收6345萬元,毛利率為23.3%。在模具、塑料產品配件和智能裝備三大基礎業務中為毛利率最高的業務。今後將繼續利用現有渠道優勢,加大客户開拓,提升智能裝備產量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.